Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet function and interferon alpha-2a treatment in essential thrombocythaemia.

L Catani1, L Gugliotta, M L Cascione

  • 1Haematology Institute L. & A. Seràgnoli, University of Bologna, Italy.

European Journal of Haematology
|March 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Use of Thrombopietin Receptor Agonists (Tpo-Ras) in Clinical Practice: Results from an Italian Survey on Behalf of the Gimema Working Group Anemia and Thrombocytopenia.

Mediterranean journal of hematology and infectious diseases·2025
Same author

Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.

Annals of hematology·2024
Same author

Simple, inexpensive, and rapid approach to detect changes in the structure of soil free-living nematodes.

Helminthologia·2024
Same author

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.

Annals of hematology·2024
Same author

Possible involvement of HtrA1 serine protease in the onset of osteoporotic bone extracellular matrix changes.

Tissue & cell·2024
Same author

A driving simulation study on the effects of different wine types on the performance of young drivers.

Drug and alcohol dependence·2021

Interferon (IFN) alpha-2a treatment for essential thrombocythaemia (ET) reduces platelet counts but only partially improves platelet function abnormalities. The delta-storage pool deficiency persists despite therapy.

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Essential thrombocythaemia (ET) is characterized by elevated platelet counts and qualitative platelet dysfunction.
  • Platelet abnormalities in ET include impaired in vitro aggregation and delta-storage pool deficiency.

Purpose of the Study:

  • To evaluate the effects of interferon (IFN) alpha-2a on platelet function in patients with ET.
  • To assess whether IFN alpha-2a corrects the qualitative platelet defects associated with ET.

Main Methods:

  • Prospective study of 20 ET patients treated with IFN alpha-2a.
  • Evaluation of in vitro platelet aggregation, intraplatelet adenosine diphosphate (ADP) levels, plasma beta-thromboglobulin (beta-TG), and platelet beta-TG.

Main Results:

  • IFN alpha-2a significantly reduced platelet counts in all patients.

Related Experiment Videos

  • Partial improvement in in vitro platelet aggregation was observed in most patients.
  • Intraplatelet ADP levels improved but remained below normal, indicating persistent delta-storage pool deficiency.
  • Plasma beta-TG levels decreased significantly, while platelet beta-TG and beta-TG ratio remained normal, suggesting no platelet activation.

    • Conclusions:

    • IFN alpha-2a partially corrects qualitative platelet abnormalities in ET.
    • Despite reducing platelet count, IFN alpha-2a does not fully restore normal platelet function in ET patients.
    • Persistent delta-storage pool deficiency highlights limitations of IFN alpha-2a in addressing ET-related platelet defects.